Provided by Tiger Trade Technology Pte. Ltd.

Monte Rosa Therapeutics

14.56
+0.78505.70%
Pre-market: 14.670.1100+0.76%05:12 EDT
Volume:1.10M
Turnover:15.89M
Market Cap:1.24B
PE:-8.34
High:14.84
Open:14.06
Low:14.00
Close:13.78
52wk High:25.77
52wk Low:4.54
Shares:85.31M
Float Shares:54.48M
Volume Ratio:0.89
T/O Rate:2.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7450
EPS(LYR):-0.4650
ROE:-42.66%
ROA:-21.63%
PB:2.55
PE(LYR):-31.31

Loading ...

BRIEF-Monte Rosa Therapeutics Q4 Operating Income USD -49.715 Million

Reuters
·
Mar 17

Monte Rosa Therapeutics Q4 Net Income USD -46.135 Million

THOMSON REUTERS
·
Mar 17

Monte Rosa Therapeutics Q4 Operating Expenses USD 52.496 Million

THOMSON REUTERS
·
Mar 17

Press Release: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Dow Jones
·
Mar 17

BUZZ-U.S. STOCKS ON THE MOVE-Customers Bancorp, Forgent Power Solutions, Nvidia

Reuters
·
Mar 17

BUZZ-U.S. STOCKS ON THE MOVE-Dollar Tree, Micron, Customers Bancorp

Reuters
·
Mar 16

Monte Rosa Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview

Reuters
·
Mar 16

Monte Rosa Therapeutics Announces Clinical Supply Agreement To Support Phase 2 Trial Evaluating Mrt-2359 In Combination With Apalutamide For The Treatment Of Metastatic Castration-Resistant Pros

Reuters
·
Mar 16

BUZZ-U.S. STOCKS ON THE MOVE-Sable Offshore, Nebius, Upstart

Reuters
·
Mar 16

BUZZ-Monte Rosa rises on lining up new combo trial in advanced prostate cancer

Reuters
·
Mar 16

Monte Rosa to launch Phase 2 trial of MRT-2359 plus apalutamide in AR-mutant mCRPC in Q3 2026

Reuters
·
Mar 16

Monte Rosa Therapeutics Inc - to Conduct and Sponsor Trial; Johnson & Johnson to Supply Erleada

THOMSON REUTERS
·
Mar 16

Monte Rosa Therapeutics Inc - to Initiate Phase 2 Study of Mrt-2359 With Apalutamide in Q3 2026

THOMSON REUTERS
·
Mar 16

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 11

Monte Rosa Therapeutics CEO Markus Warmuth Disposes of Common Shares

Reuters
·
Mar 05

Monte Rosa Therapeutics Principal Accounting Officer Edmund Dunn Disposes of Common Shares

Reuters
·
Mar 03